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Mutant huntingtin proteolysis mediated by various proteases plays a key role in Huntington’s disease (HD)
pathogenesis. In this issue of Neuron, Miller et al. have identified 11 proteases, including matrix metallopro-
teinases (MMPs), that when inhibited reduce huntingtin proteolysis and produce beneficial therapeutic
effects. These findings provide new insights into huntingtin proteolysis and its potential as a therapeutic
target.Huntington’s disease, the most frequent
of a group of nine inherited neurodegener-
ative polyglutamine disorders, is caused
by an expandedCAG triplet repeat in exon
1 of the huntingtin gene that encodes
a stretch of polyglutamine (polyQ) resi-
dues close to the N-terminus of the hun-
tingtin (Htt) protein. Expansion of the
polyglutamine repeat interferes with the
interaction of N-terminal 17 amino acid
sequence of huntingtin (NT-17) with the
nuclear exporter translocated promoter
region (Tpr), causing accumulation of
mutant huntingtin in the nucleus. Hunting-
tin aggregates, predominantly composed
of N-terminal fragments of polyQ
expanded Htt, in the nucleus and cyto-
plasm of affected neurons are a patholog-
ical hallmark of HD (Wheeler et al., 2000;
DiFiglia et al., 1997).
Htt is known to be cleaved by various
intracellular proteases, including cas-
pases 1, 3, 6, 7, and 8; calpain; and an
unidentified aspartic protease. Caspases
and calpains are the most widely studied
andcleaveHttwithin theN-terminal region
between amino acids 469 and 586 (Gafni
et al., 2004; Wellington et al., 2000).
Recent work identified Htt cleavage sites
closer to the N terminus, between amino
acids 105 and 167 (Lunkes et al., 2002;
Ratovitski et al., 2007).
Inhibition of mutant Htt cleavage
reduces toxicity, indicating an important
role for Htt proteolysis in HD pathogen-
esis (Graham et al., 2006; Gafni et al.,
2004). An initial transgenic mouse model
expressing an N-terminal fragment with
about 150 CAG repeats, the R6/2 mouse,
developed a robust behavioral pheno-
type, striatal atrophy, and reducedsurvival (Mangiarini et al., 1996). The
N-terminal 171 amino acid Htt fragment
(N171-82Q mice) is also toxic, whereas
the N-terminal 117 amino acid fragment
(N117) does not convey the HD
phenotype in the ‘‘shortstop’’ mice (Slow
et al., 2005). As a general rule, shorter
N-terminal Htt fragments produce
a more robust phenotype in transgenic
mice than does full-length Htt. In vitro
studies showed that calpain cleavage of
mutant Htt plays a critical role in its path-
ogenicity (Gafni et al., 2004). Furthermore,
a putative aspartyl protease site near the
N terminus of mutant Htt has been
implicated in the generation of toxic frag-
ments (Lunkes et al., 2002). Studies also
showed that a caspase 6 cleavage site
plays a critical role in disease pathogen-
esis, since mutating this site so that it
cannot be cleaved abolishes the pathoge-
nicity of mutant Htt in vivo (Graham et al.,
2006). More recent studies have demon-
strated that, apart from the proteolytic
cleavage, N-terminal modifications such
as phosphorylation of serines 13 and 16
play a critical role in the toxicity of mutant
Htt in vivo (Gu et al., 2009). The studies to
date have therefore shown that proteo-
lytic cleavage of mutant Htt, as well as
N-terminal modifications, can play a crit-
ical role in the disease pathogenesis.
Although important caspase and cal-
pain cleavage sites have been identified,
it is unknown whether other proteases
play an important role in Htt cleavage
and pathogenicity. A study by Miller
et al. (2010) in this issue of Neuron exam-
ined huntingtin proteolytic processing by
screening for enzymes that cleave mutant
Htt. In an elegant and novel approachNeuronusing an unbiased RNAi screen consisting
of 514 siRNAs targeting the repertoire of
all known and predicted human protease
genes, they identified proteases that
produce toxic N-terminal Htt proteolytic
fragments. Htt cleavage sites closer to
the N terminus produce smaller, and
potentially more toxic, mutant Htt frag-
ments. They used a high-throughput
western-blot-based screen to detect the
generation of small N-terminal Htt frag-
ments with the 1C2 antibody, which
selectively recognizes conformationally
altered stretches of increased polyglut-
amines. In their system, a 55 kDa product
was the smallest detectable Htt cleavage
product; therefore, they predicted that
blocking production of this fragment
would prevent Htt-mediated cell death.
The screen identified 11 proteases that,
when inhibited, reduced huntingtin frag-
ment accumulation detected by the 1C2
anti-polyQ antibody. The proteases iden-
tified include members of the calpain
family, which are increased in HD trans-
genic mice and postmortem human brain
tissue (CAPN5 and CAPN7); the signal
peptide protease-like IMP5 and an
amino-terminal signal peptide protease
(SPC18); members of the secreted
serine-protease kallikrein family (KLK10
and KLK11); the transmembrane-E3-
ubiquitin ligase, RNF128; the MMP-2
interacting integrin, ITGA2B; and three
members of the matrix metalloproteinase
family (MMP-10, -14, -23B). Nine of the 11
proteases are expressed in striatal cells,
and their knockdown significantly
reduced Htt-mediated striatal cell death
in a secondary cellular toxicity screen.
They identified several interesting67, July 29, 2010 ª2010 Elsevier Inc. 171
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Figure 1. MMP-10 in Proteolytic Processing of Huntingtin
(A) MMP-10 is increased in HD and involved in direct cleavage of Htt, thereby producing small N-terminal
toxic fragments.
(B) Pharmacological interventions such as MMP inhibitors or genetic manipulations such as overexpress-
ing HDAC7, which acts as repressor for MMP-10, may provide a therapeutic benefit by reducing the
cleavage of mutant Htt.
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Previewsproteases including (1) IMP5, an unusual
aspartyl protease that mediates clear-
ance of signal peptides by proteolysis
within endoplasmic reticulum and (2)
RFN128, a ubiquitin E3 ligase that pro-
motes proteasomal degradation. Further
studies are needed to establish the inter-
action between Htt and these proteases.
Of the nine proteases validated by the
secondary screen, Miller et al. found that
three are matrix metalloproteinase
(MMP) family members (MMP-10, -14,
-23B) and one (ITGA2B) interacts with
MMP-2, indicating an important role of
MMPs in Htt proteolysis and toxicity.
MMPs are a family of zinc-containingmet-
alloproteinases that normally remodel the
extracellular matrix and are implicated in
neurodegeneration. They initially con-
firmed that MMP-10 and -14 are present
in Hdh111Q/111Q striatal cells by western
blotting. Then, they found that the knock-
down of MMP-10 and -14 using siRNA
correlated with a reduction in caspase
activity. Then, they showed that apharma-
cologic inhibitor, NNGH, which is a non-
peptidic, potent inhibitor of MMPs, and
two known endogenous inhibitors of172 Neuron 67, July 29, 2010 ª2010 ElsevierMMPs, TIMP1 and TIMP3, blocked
Htt-mediated toxicity in the striatal
Hdh111Q/111Q cells. The MMPs were pro-
cessed to their active forms, and the
levels of MMP-10 and -14 were increased
in Hdh111Q/111Q cells, as compared to
HdhQ7/Q7 cells. MMP-10 enzymatic ac-
tivity was significantly increased in
Hdh111Q/111Q cells as compared to
HdhQ7/Q7 cells. These findings were reca-
pitulated when tested in the brains of
a full-length Htt (YAC128) and N-terminal
fragment mouse model (R6/2) of HD.
They examined whether MMPs cleave
mutant Htt directly by incubating cell
lysates expressing Htt with recombinant
MMPs. They found that Htt (wild-type or
mutant) expressed in cellular lysates is
a substrate for MMP-10, but not for
MMP-14 or -2. Using in vitro translation
studies, they demonstrated that MMP-
10 knockdown suppresses Htt toxicity,
through a direct effect on Htt cleavage.
They examined the effects of reducing
the expression of MMPs on Htt-induced
neuronal dysfunction in a HD Drosophila
model. In this model system, neuron-
specific expression of expandedHtt leadsInc.to quantifiable progressive motor deficits.
Of the two Drosophila MMP genes, only
Dm2-MMP is expressed in postembry-
onic brain, and heterozygous loss-of-
function alleles of Dm2-MMP showed
robust and significant effects in improving
the motor performance of the flies. Partial
loss of function in Drosophila homologs of
CAPN5, CAPN7, IMP5, and RNF128 also
ameliorated motor deficits in the HD
Drosophila model. Photoreceptor degen-
eration is also reduced in Drosophila
expressing NT-Htt[128Q] with decreased
levels of CalpA, Sol, and Dm2-MMP.
To summarize, Miller et al. identified
several novel cleavage enzymes involved
in huntingtin proteolytic processing, in-
cluding MMP-10, a matrix metalloprotei-
nase. They demonstrate increased MMP
activity in HD mice, direct cleavage of
Htt by MMP-10 (Figure 1A), and preven-
tion of cell death on knockdown of
MMP-10 in striatal HdhQ111/Q111 cells
and a HD Drosophila model. They local-
ized the MMP-10 cleavage site to a small
region (a region closer to the N terminus
than the caspase and calpain cleavage
products of 55–72 kDa, producing
a smaller 48 kDa product) and putative
single amino acid residue (amino acid
402). Earlier studies in HD transgenic
mice with a regulatable expression of
mutant Htt showed that inhibiting expres-
sion of mutant Htt in symptomatic mice
improved the neurological phenotype
and caused the intranuclear inclusions to
disappear (Yamamoto et al., 2000; DiFi-
glia et al., 2007). Mice expressing mutant
Htt, resistant to cleavage by caspase-6,
maintain normal neuronal function and
do not develop striatal neurodegeneration
(Graham et al., 2006). Similarly, inhibition
of calpains leads to decreased proteolytic
processing and aggregation of polyQ
expanded Htt, resulting in decreased
toxicity in an in vitro cell model (Gafni
et al., 2004). These observations indicate
that both the behavioral phenotype and
the presence of intranuclear inclusions
require continuous supplies of the
abnormal huntingtin fragments and that
the cleavage events are rate-limiting
steps in pathogenesis.
The importance of the observations
of Miller et al. (2010) is that they identify
new therapeutic targets for the treatment
of HD, and in particular the involvement of
MMP-10 in HD pathogenesis. MMP-10
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Previewsis present in neurons, and it was
increased in the striatum of R6/2 and
YAC128 transgenic mice. Genetic or
pharmacological interventions that block
MMP-mediated production of Htt frag-
ments therefore provide a target for
therapeutic intervention (Figure 1B). If
a selective inhibitor of MMP-10 can be
developed, then this could be tested in
transgenic mice and eventually in
patients. We showed the feasibility of
utilizing an MMP inhibitor therapeutically
in another neurodegenerative disease, in
a transgenic mousemodel of ALS (Lorenzl
et al., 2006). To investigate this further, it
would be of interest to produce a trans-
genic HD mouse in which the MMP-10
site is mutated, such that it cannot be
cleaved, and then to determine whether
this abolishes the disease phenotype
and pathology, similar to observations
with caspase 6. It will also be of interest
to cross MMP-10 knockout mice with
full-length transgenic mouse models of
HD. Activation of MMP-10 is known to
occur in response to histone deacetylase
7 (HDAC7) knockdown (Chang et al.,
2006); thus, another interesting approachto achieve downregulation of MMP-10
may be to increase expression of
HDAC7 in HD cells, or transgenic mice
and investigate whether this ameliorates
HD pathology.REFERENCES
Chang, S., Young, B.D., Li, S., Qi, X., Richardson,
J.A., and Olson, E.N. (2006). Cell 126, 321–334.
DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W.,
Bates, G.P., Vonsattel, J.P., and Aronin, N.
(1997). Science 277, 1990–1993.
DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp,
E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pan-
dey, R.K., Rajeev, K.G., et al. (2007). Proc. Natl.
Acad. Sci. USA 104, 17204–17209.
Gafni, J., Hermel, E., Young, J.E., Wellington, C.L.,
Hayden, M.R., and Ellerby, L.M. (2004). J. Biol.
Chem. 279, 20211–20220.
Graham, R.K., Deng, Y., Slow, E.J., Haigh, B.,
Bissada, N., Lu, G., Pearson, J., Shehadeh, J.,
Bertram, L., Murphy, Z., et al. (2006). Cell 125,
1179–1191.
Gu, X., Greiner, E.R., Mishra, R., Kodali, R.,
Osmand, A., Finkbeiner, S., Steffan, J.S.,
Thompson, L.M., Wetzel, R., and Yang, X.W.
(2009). Neuron 64, 828–840.NeuronLorenzl, S., Narr, S., Angele, B., Krell, H.W.,
Gregorio, J., Kiaei, M., Pfister, H.W., and Beal,
M.F. (2006). Exp. Neurol. 200, 166–171.
Lunkes, A., Lindenberg, K.S., Ben-Haiem, L.,
Weber, C., Devys, D., Landwehrmeyer, G.B., Man-
del, J.L., and Trottier, Y. (2002). Mol. Cell 10,
259–269.
Mangiarini, L., Sathasivam, K., Seller, M., Cozens,
B., Harper, A., Hetherington, C., Lawton, M.,
Trottier, Y., Lehrach, H., Davies, S.W., and Bates,
G.P. (1996). Cell 87, 493–506.
Miller, J.P., Holcomb, J., Al-Ramahi, I., de Haro,
M., Gafni, J., Zhang, N., Kim, E., Sanhueza, M.,
Torcassi, C., Kwak, S., et al. (2010). Neuron 67,
this issue, 199–212.
Ratovitski, T., Nakamura, M., D’Ambola, J.,
Chighladze, E., Liang, Y., Wang, W., Graham, R.,
Hayden, M.R., Borchelt, D.R., Hirschhorn, R.R.,
and Ross, C.A. (2007). Cell Cycle 6, 2970–2981.
Slow, E.J., Graham, R.K., Osmand, A.P., Devon,
R.S., Lu, G., Deng, Y., Pearson, J., Vaid, K.,
Bissada, N., Wetzel, R., et al. (2005). Proc. Natl.
Acad. Sci. USA 102, 11402–11407.
Wellington, C.L., Leavitt, B.R., and Hayden, M.R.
(2000). J. Neural Transm. Suppl., 1–17.
Wheeler, V.C., White, J.K., Gutekunst, C.A.,
Vrbanac, V., Weaver, M., Li, X.J., Li, S.H., Yi, H.,
Vonsattel, J.P., Gusella, J.F., et al. (2000). Hum.
Mol. Genet. 9, 503–513.
Yamamoto, A., Lucas, J.J., and Hen, R. (2000). Cell
101, 57–66.Going Tubular in the Rostral Migratory Stream:
Neurons Remodel Astrocyte Tubes to Promote
Directional Migration in the Adult BrainTae-Yeon Eom,1 Jingjun Li,1 and E.S. Anton1,*
1Neuroscience Center and the Department of Cell andMolecular Physiology, The University of North Carolina School of Medicine, Chapel Hill,
NC 27599, USA
*Correspondence: anton@med.unc.edu
DOI 10.1016/j.neuron.2010.07.013
Newly generated neuroblasts from the subventricular zone of the adult brain migrate as neuronal chains
within a network of astroglial tubes in the rostral migratory stream. This highly directed, rapidmigration chan-
nels new neurons to the olfactory bulb. In this issue of Neuron, Kaneko et al. demonstrate that migrating
neurons dynamically remodel the morphology and organization of astroglial tubes to promote long distance,
directional migration of neurons in the adult brain.Reciprocal interactions between migrat-
ing neurons and astroglia play influential
roles in the guidance and placement of
newly generated neurons in the cerebralcortex. During embryonic development,
migrating neurons modulate the function
of radial glial cells as neuronal migratory
guides in the neocortex (Hatten, 1985;Rakic, 2003). In contrast, in the adult
brain, long distance neuronal migration
is thought to occur in a glial-independent
manner. In the rostral migratory stream67, July 29, 2010 ª2010 Elsevier Inc. 173
